-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42

Benzinga·01/22/2026 14:19:23
Listen to the news
Oppenheimer analyst Andreas Argyrides initiates coverage on Evommune (NYSE:EVMN) with a Outperform rating and announces Price Target of $42.